Timothy P Cripe

13PUBLICATIONS

45CO-AUTHORS

Molecular targetsEthical use of new technologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Jun 22, 2026

Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumors.

|Apr 07, 2025

Clinical Trials or FDA-Approved Therapies? The Ethics of Sickle Cell Gene Therapy Access.

Timothy P Cripe, Anthony D Villella

|Jan 08, 2025

Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer.

Emily Schwarz, Himanshu Savardekar, Sara Zelinskas

|Sep 12, 2024

Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy.

Wen Luo, Hai Hoang, Hongwen Zhu

|Mar 11, 2024

Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma.

Emily M Ringwalt, Mark A Currier, Andrea M Glaspell

|Jul 20, 2022

Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics.

Timothy P Cripe, Brian Hutzen, Mark A Currier

Pageof 3

Frequent Collaborators

2 joint publications

Dean Lee

2 joint publications

Mary Frances Wedekind

Joseph R Stanek

Emily M Ringwalt

Kevin A Cassady

Mitchell S Cairo

Lars M Wagner

Kellie B Haworth

Nicole S Bryce

Justine Stehn

Frequent Collaborators

2 joint publications

Dean Lee

2 joint publications

Mary Frances Wedekind

2 joint publications

Joseph R Stanek

2 joint publications

Emily M Ringwalt